Between The Lines: Guidelines for Use and Dosing of Selinexor in Multiple Myeloma

Opening their discussion on relapsed/refractory multiple myeloma, Joshua Richter, MD and Peter Forsberg, MD review options for treatment sequencing, initiating treatment, and the mechanism of action for selinexor.

Two subject matter experts discuss keystone trials supporting the use of Selinexor in patients with R/R MM, each with unique dosing structures and different selinexor-based combinations.

Discourse centered around dosing strategies for selinexor-based therapies.

Insights on supportive care measures to minimize or counter common adverse effects for patients with R/R MM taking selinexor-based therapies

Dr. Joshua Richter and Dr. Peter Forsberg close their discission with thoughtful advice for clinicians regarding the current and future treatment of patients with R/R MM.

In a recent Between the Lines, Joshua Richter, MD, and Peter Forsberg, MD, discussed a recent commentary on weekly dosing and supportive care solutions for selinexor in patients with multiple myeloma, and provided a general overview of the agent in this treatment landscape.